Table 4.

Incidence of total polyps and adenomas 1 year after treatment

PlaceboSulindacEtodolac
Subjects with polypectomyn = 48n = 48n = 47
 Incidence of total polyps26/48 (54.2%)15/48 (31.3%)24/47 (46.8%)
 Risk ratio (95% CI)0.39 (0.17–0.89)0.96 (0.43–2.15)
P valuea 0.0250.92
 Incidence of adenomas24/48 (50.0%)14/48 (29.2%)21/47 (44.7%)
 Risk ratio (95% CI)0.41 (0.18–0.96)0.81 (0.36–1.81)
P valuea 0.0390.60
Polyp-free subjectsn = 9n = 9n = 10
 Incidence of total polyps2/9 (22.2%)2/9 (22.2%)2/10 (20.0%)
 Risk ratio (95% CI)1.00 (0.11–9.23)0.88 (0.10–7.95)
P valuea 1.000.91
 Incidence of adenomas1/9 (11.1%)2/9 (22.2%)2/10 (20.0%)
 Risk ratio (95% Cl)2.29 (0.17–31.0)2.00 (0.15–26.7)
P valuea 0.530.60
All subjectsn = 57n = 57n = 57
 Incidence of total polyps28/57 (49.1%)17/57 (29.3%)26/57 (45.6%)
 Risk ratio (95% Cl)0.44 (0.20–0.95)0.87 (0.42–1.81)
P valuea 0.0370.71
 Incidence of adenomas25/57 (43.9%)16/57 (28.1%)23/57 (40.4%)
 Risk ratio (95% Cl)0.50 (0.23–1.09)0.87 (0.41–1.82)
P valuea 0.080.70
  • aLogistic regression analysis was used to calculate P values.